Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
21 June 2017
E-003085/2017
Answer given by Mr Andriukaitis on behalf of the Commission

The organisation of health systems and delivery of care as well as the cost containment measures in the area of medicine are the responsibility of Member States.

The Commission is supporting improved exchange of information among Member States and promoting their cooperation on a voluntary basis for example through the Network of competent authorities responsible for pricing and reimbursement(1), by supporting a European medicine price data base(2) focusing on the appropriate use of current data sets of product prices and implementing effective application of reference pricing to participating Member States and by supporting a Project on Sustainable Access to Innovative Therapies(3).

To respond to a call by the Council in 2016(4), the Commission has commissioned a study to analyse the impact of pharmaceutical incentives on innovation, availability and accessibility of medicinal products. The study will be carried out in the course of 2017.

The Commission is working on an initiative to strengthen EU cooperation on health technology assessment(5). Finally, the Commission has also mandated the Expert Panel on Effective Ways of Investing in Health(6) to develop an Opinion on ‘Innovative payment models for high-cost innovative medicines’, which would assist Member States to develop policies on cost-effective use of medicines.

(1)Known as CAPR
(2)Euripid project http://ec.europa.eu/chafea/news/news492.html
(3)OECD Project on Sustainable Access to Innovative Therapies http://www.oecd.org/els/health-systems/pharmaceuticals.htm
(4)Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States: http://www.consilium.europa.eu/en/press/press-releases/2016/06/17-epsco-conclusions-balance-pharmaceutical-system/
(5)http://ec.europa.eu/smart-regulation/roadmaps/docs/2016_sante_144_health_technology_assessments_en.pdf
(6)http://ec.europa.eu/health/expert_panel/

Last updated: 28 June 2017Legal notice